Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review

被引:71
作者
Schultz, Neil M. [1 ]
Bhardwaj, Shweta [2 ]
Barclay, Claudia [2 ]
Gaspar, Luis [3 ]
Schwartz, Jason [1 ]
机构
[1] Astellas Pharma Inc, 1 Astellas Way, Northbrook, IL 60062 USA
[2] IQVIA, London, England
[3] IQVIA, Reading, Berks, England
关键词
burden; costs; dry age-related macular degeneration; epidemiology; management; quality of life; RISK-FACTORS; EYE DISEASE; PREVALENCE; HEALTH; POPULATION; PATIENT; COSTS; AREDS;
D O I
10.1016/j.clinthera.2021.08.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: Age-related macular degeneration (AMD) is a leading cause of blindness, particularly in higher income countries. Although dry AMD accounts for 85% to 90% of AMD cases, a comprehensive understanding of the global dry AMD burden is needed. Methods: A targeted literature review was conducted in PubMed, MEDLINE, Embase, and the Cochrane Database of Systematic Reviews (19952019) to identify data on the epidemiology, management, and humanistic and economic burden of dry AMD in adults. A landscape analysis of patient reported outcome (PRO) instruments in AMD was also conducted via searches in PubMed (1995-2019), ClinicalTrials.gov, PROQOLID, PROLABELS, and health technology assessment reports (2008-2018). Findings: Thirty-seven of 4205 identified publications were included in the review. Dry AMD prevalence was 0.44% globally, varied across ethnic groups, and increased with age. Patients with dry AMD had higher risks of all-cause mortality (hazard ratio [HR] = 1.46; 95% CI, 0.99-2.16) and tobacco-related (HR = 2.86; 95% CI, 1.15-7.09) or cancer deaths (HR = 3.37; 95% CI, 1.56-7.29; P = 0.002) than those without dry AMD. Smoking, increasing age or cholesterol levels, and obesity are key risk factors for developing dry AMD. No treatment guidelines were identified for dry AMD specifically; management focuses on risk factor reduction and use of dietary supplements. In the United States and Italy, direct medical costs and health care resource utilization were lower in patients with dry versus wet AMD. Patients with dry AMD, particularly advanced disease, experienced significant visual function impairment. Dry AMD symptoms included reduced central vision, decreased ability to see at night, increased visual blurriness, distortion of straight lines and text, and faded color vision. Most PRO instruments used in AMD evaluations covered few, if any, of the identified symptoms reported by patients with dry AMD. Although the Quality of Life and Vision Function Questionnaire, 25-item National Eye Institute Vision Function Questionnaire, Low Vision Quality of Life, Impact of Vision Impairment-Very Low Vision, and Functional Reading Independence Index had strong content validity and psychometric properties in patients with dry AMD, they retained limited coverage of salient concepts. Implications: Despite dry AMD accounting for most AMD cases, there are substantial gaps in the published literature, particularly the humanistic and economic burden of disease and the lack of differentiation among dry, wet, or unspecified dry AMD. The significant burden of illness alludes to a high unmet need for tolerable and effective treatment options, as well as PRO instruments with more coverage of dry AMD symptoms and salient concepts. (Clin Ther. 2021;43:1792- 1808.) (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC ND license ( http://creativecommons.org/licenses/bync-nd/4.0/ )
引用
收藏
页码:1792 / +
页数:27
相关论文
共 54 条
[41]   A Review of Current and Future Management of Geographic Atrophy [J].
Sacconi R. ;
Corbelli E. ;
Querques L. ;
Bandello F. ;
Querques G. .
Ophthalmology and Therapy, 2017, 6 (1) :69-77
[42]  
Schmier J, 2017, VALUE HEALTH, V20, pA160
[43]   The burden of age-related macular degeneration [J].
Schmier, JK ;
Jones, ML ;
Halpern, MT .
PHARMACOECONOMICS, 2006, 24 (04) :319-334
[44]  
Schmier JK, 2017, QUAL LIFE RES, V26, P123
[45]   Patterns and Costs Associated With Progression of Age-Related Macular Degeneration [J].
Schmier, Jordana K. ;
Covert, David W. ;
Lau, Edmund C. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2012, 154 (04) :675-681
[46]   The Patient Experience: Symptoms and Impact of Dry Age-Related Macular Degeneration [J].
Schultz, Neil M. ;
Braunack-Mayer, Lydia ;
Schwartz, Jason ;
Gaspar, Luis .
OPHTHALMOLOGY AND THERAPY, 2021, 10 (01) :151-164
[47]  
Scottish Intercollegiate Guidelines Network, Methodology Checklist 3: cohort studies
[48]   How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review [J].
Taylor, Deanna J. ;
Hobby, Angharad E. ;
Binns, Alison M. ;
Crabb, David P. .
BMJ OPEN, 2016, 6 (12)
[49]   Risk factors for incident age-related macular degeneration - Pooled findings from 3 continents [J].
Tomany, SC ;
Wang, HJ ;
van Leeuwen, R ;
Klein, R ;
Mitchell, P ;
Vingerling, JR ;
Klein, BEK ;
Smith, W ;
de Jong, PTVM .
OPHTHALMOLOGY, 2004, 111 (07) :1280-1287
[50]   Prevalence of Age-Related Macular Degeneration in Chinese American Adults The Chinese American Eye Study [J].
Varma, Rohit ;
Choudhury, Farzana ;
Chen, Sardius ;
Wu, Shuang ;
Hsu, Chunyi ;
Torres, Mina ;
Klein, Ronald ;
Azen, Stanley P. ;
McKean-Cowdin, Roberta .
JAMA OPHTHALMOLOGY, 2016, 134 (05) :571-577